Furthermore, other members of the SWI/SNF complex are frequently lost or mutated in cancers [4, 28], and it will be of interest to investigate whether altered SWI/SNF activity through mutation or expression changes of a given complex subunit in general predicts sensitivity to EZH2 inhibition. This evidence concerns the gene SMARCA1 and cancer.